Jubilant Life Sciences shares gained as much as 3.5 per cent intraday on Wednesday after the company informed BSE that it has received approval from the US health regulator to market Indomethacin capsule used for treating pains.
At 12.39 pm, Jubilant Life Sciences shares were trading 1.27 per cent up at Rs 401.70 a share. The scrip opened at Rs 400.90 and had touched a high and low of Rs 410.60 and Rs 397, respectively, in trade so far. Sensex was up 32.20 points, or 0.12 per cent, at 26,965.08.
In a BSE filing, Jubilant Life Sciences said, ” It received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (USFDA) for Indomethacin ER Capsule 75mg, which is a non-steriodal anti-inflammatory drug used for treatment of pain”.
As on June 30, 2015, Jubilant Life Sciences had a total of 815 filings for formulations of which 389 have been approved in various regions globally. This includes 72 ANDAs filed in the US, of which 38 have been approved and 46 Dossier filings in Europe.
In the past one year, the share price of the company jumped 159 per cent to Rs 396.65 on October 6 from Rs 152.60 on October 7 last year. Sensex gained 2.5 per cent during the same period.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 410.60 on 07-Oct-2015 and a 52 week low of Rs. 116.10 on 17-Dec-2014.
Last one week high and low of the scrip stood at Rs. 410.60 and Rs. 357.50 respectively. The current market cap of the company is Rs. 6,329.00 crore.
The promoters holding in the company stood at 54.02% while Institutions and Non-Institutions held 17.73% and 28.24% respectively.
Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Specialty Pharmaceuticals and Life Science Ingredients.
Subscribe To Our Free Newsletter |